{"schema_version":"secwatch.filing_event.v1","accession":"0001653477-25-000104","form_type":"8-K","ticker":"NGVT","cik":"0001653477","company_name":"Ingevity Corp","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.569114+00:00","generated_at":"2026-05-17T21:29:10.834131+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ingevity posts Q2 net loss of $146.5M on $183.8M goodwill impairment; adjusted EPS up 38% to $1.39","bullets":["Net sales $365.1M, down 7% YoY, led by lower Performance Chemicals volumes.","Net loss $146.5M ($4.02 diluted loss) includes $183.8M non-cash goodwill impairment.","Adjusted earnings $51.1M (+39%); adjusted diluted EPS $1.39 (+38%).","Adjusted EBITDA $110.0M (+9%), margin improved to 30.1% on repositioning actions.","Raises low-end of adjusted EBITDA guidance to $390–$415M; sales guidance reaffirmed at $1.25–$1.40B."],"urls":{"canonical":"https://secwatch.observer/filing/0001653477-25-000104","json":"https://secwatch.observer/filing/0001653477-25-000104.json","markdown":"https://secwatch.observer/filing/0001653477-25-000104.md","text":"https://secwatch.observer/filing/0001653477-25-000104.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1653477/000165347725000104/0001653477-25-000104-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1653477/000165347725000104/ngvt-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:29:10.834131+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}